Jazz Pharmaceuticals PLC (JAZZ)
NASDAQ · Healthcare · Biotechnology
Jazz Pharmaceuticals PLC is a Healthcare company with a market capitalization of $15.96B and a trailing P/E ratio of 16.8.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | $6.34 | $4.66 | +36.0% |
| Q4 2025 | February 24, 2026 | $6.64 | $6.51 | +2.1% |
| Q3 2025 | November 5, 2025 | $6.99 | $4.80 | +45.6% |
| Q2 2025 | August 5, 2025 | $-8.25 | $-6.25 | -32.0% |
| Q1 2025 | May 6, 2025 | $1.68 | $4.66 | -63.9% |
| Q4 2024 | February 25, 2025 | $6.60 | $5.81 | +13.6% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 3,801,863 | 5.75% | 4.8 | +8.6% |
| June 30, 2026 | 3,500,138 | 5.30% | 3.8 | -11.2% |
| June 15, 2026 | 3,941,396 | 5.96% | 4.2 | -8.1% |
| May 29, 2026 | 4,290,867 | 6.49% | 5.1 | -11.5% |
| May 15, 2026 | 4,849,332 | 7.34% | 4.7 | -4.7% |
| April 30, 2026 | 5,090,611 | 8.35% | 5.3 | -2.9% |
| April 15, 2026 | 5,240,459 | 8.59% | 6.0 | -19.7% |
| March 31, 2026 | 6,526,407 | 10.70% | 8.0 | +5.9% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Jazz Pharmaceuticals PLC's market cap?
As of August 13, 2026, Jazz Pharmaceuticals PLC (JAZZ) has a market capitalization of $15.96B.
What is Jazz Pharmaceuticals PLC's P/E ratio?
Jazz Pharmaceuticals PLC trades at a trailing price-to-earnings (P/E) ratio of 16.8. Its forward P/E is 10.3.
Does Jazz Pharmaceuticals PLC pay a dividend?
Jazz Pharmaceuticals PLC does not currently pay a dividend.
What sector is JAZZ in?
Jazz Pharmaceuticals PLC is in the Healthcare sector, specifically the Biotechnology industry.
What is Jazz Pharmaceuticals PLC's short interest?
As of the July 15, 2026 FINRA settlement, 3,801,863 JAZZ shares were sold short, or 5.75% of shares outstanding. Days to cover: 4.8. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Jazz Pharmaceuticals PLC's revenue?
In its latest reported fiscal year (ending December 31, 2025), Jazz Pharmaceuticals PLC reported revenue of $4.27B and net income of -$356.15M.
Ask your own questions about JAZZ
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.